The webinar discussed the growing initiatives to force pharmaceutical manufacturers to highlight the generic name of the active compound with much greater relevance than the brand name and how this can affect trademark law and the ability to distinguish products on the market, which would go against free competition.
You can access the recording of this webinar in:
https://attendee.gotowebinar.com/recording/3028234657161647884
View recording
